Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 47

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 47
---
| Name                        |     | Age |     | Position(s) with the                                   
 combined company                                       |     | Current Position(s)                                          |
| Ronen Twito                 |     |  50 |     | Executive Chairman nominee and Chief Executive Officer |     | Executive Chairman and Chief Executive Officer of Kadimastem |
| Prof. Michel Revel, MD, PhD |     |  86 |     | Director and Chief Scientific Officer                  |     | Director and Chief Scientific Officer of Kadimastem          |
| Kfir Molakandov PhD         |     |  47 |     | Vice President of Research and Development             |     | Vice President of Research and Development of Kadimastem     |
| Nicole Fernandez-McGovern   |     |  51 |     | Chief Financial Officer                                |     | Chief Financial Officer of NLS                               |
| Ariel Revel, MD             |     |  63 |     | Director of Medical Affairs                            |     | Director of Medical Affairs of Kadimastem                    |
| Eric Konofal, MD, PhD       |     |  57 |     | Head of DOXA Program                                   |     | Chief Scientific Officer                                     |

Q.What are the tax consequences of the Merger to me? You are urged to consult with your own tax advisor for a full understanding of the tax consequences of the Merger to you, including the consequences under any applicable, state, local, foreign or other tax laws. The Merger is not subject to Swiss withholding tax (Verrechnungssteuer).

xi For Swiss resident individuals holding NLS Common Shares or Preferred Shares as part of their private assets, the Merger should be tax neutral for purposes of Swiss federal, cantonal and communal income tax, given that the sum of the NLS share capital and capital contribution reserves after the Merger does not exceed the sum of the share capital and capital contribution reserves of NLS and Kadimastem prior to the Merger on a cumulative basis. For Swiss resident individuals as well as non -Swissresident individual taxpayers holding NLS Common Shares or Preferred Shares as part of a trade or business carried on in Switzerland, the Merger should be tax neutral for the purposes of Swiss federal, cantonal and communal tax, provided that the relevant tax book value of the shares is maintained. Otherwise, a taxable gain or tax deductible loss for the purposes of Swiss federal, cantonal and communal income tax may arise. For Swiss resident corporate taxpayers as well as non -Swissresident corporate